MDx Business Helps Meridian Q2 Revenues Spike 32 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience today reported a 32 percent jump in second quarter revenues, aided by "strong" results from its molecular diagnostic test for C. difficile and its recently acquired Bioline business.

For the three months ended March 31, Meridian posted $41.1 million in revenues, up from $31.1 million a year ago, but slightly short of consensus Wall Street expectations of $41.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.